natgillin/translations-raw huggingface dataset:
Health- Related Quality of Life (HRQoL) was assessed using the European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ-C30). 
Z zdravjem povezano kakovost življenja (HRQoL - Health-Related Quality of Life) so ocenjevali z osnovnim vprašalnikom o kakovosti življenja Evropske organizacije za raziskovanje in zdravljenje raka (EORTC QLQ-C30 - European Organization for Research and Treatment of Cancer Core
It is recommended that patients be treated for a minimum of 6 cycles. 
Priporočeno je, da se bolnike zdravi vsaj 6 ciklov.
You will usually receive at least 6 treatment cycles. 
Običajno je ciklov zdravljenja vsaj 6.
• The recommended dose is 75 mg per m2 body surface area. 
• Priporočeni odmerek je 75 mg/m2 površine telesa.
For immediate use 
Za takojšnjo uporabo
The MAH shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2. of the Marketing Authorisation and any agreed subsequent updates of the RMP. 
Imetnik dovoljenja za promet z zdravilom bo izvedel zahtevane farmakovigilančne aktivnosti in ukrepe, podrobno opisane v sprejetem RMP, predloženem v modulu 1.8.2 dovoljenja za promet z zdravilom, in vseh nadaljnjih sprejetih posodobitvah RMP.
There are no adequate data from the use of azacitidine in pregnant women. 
Ni zadostnih podatkov o uporabi azacitidina pri nosečnicah.
Other medicines and Vidaza 
Druga zdravila in zdravilo Vidaza
The effects of hepatic impairment (see section 4.2), gender, age, or race on the pharmacokinetics of azacitidine have not been formally studied. 
Učinkov motenj v delovanju jeter (glejte poglavje 4.2), spola, starosti ali rase na farmakokinetiko azacitidina niso formalno preučili.
A tumorigenicity study in rats revealed an increased incidence of testicular tumours. 
Študija tumorogenosti pri podganah je razkrila povečano pojavnost testikularnih tumorjev.
Any unused medicinal product or waste material should be disposed of in accordance with the local requirements. 
Neuporabljeno zdravilo ali odpadni material zavrzite v skladu z lokalnimi predpisi.
These are diseases which affect the bone marrow and can cause problems with normal blood cell production. 
To so bolezni, ki prizadenejo kostni mozeg in lahko povzročijo težave pri normalnem nastajanju krvnih celic.
The majority of adverse reactions occurred during the first 2 cycles and tended to decrease with subsequent cycles. 
Večina neželenih učinkov se je pojavila v prvih 2 ciklih in se je v naslednjih ciklih manjšala.
Patients and physicians are also advised to be observant for signs and symptoms of bleeding. 
Bolnike in zdravnike je treba opozoriti, da naj bodo pozorni na znake in simptome krvavenja.
Within the Intent to Treat population (ITT), the median age was 69 years (range 38 to 88 years). 
V populaciji bolnikov, ki so jih nameravali zdraviti (ITT - Intent to Treat), je bila mediana starosti 69 let (razpon 38 do 88 let).
Also, some other medicines may affect the way Vidaza works. 
Prav tako lahko nekatera druga zdravila vplivajo na način delovanja zdravila Vidaza.
Time (months) from Randomization 
Čas (meseci) od naključne razvrstitve
Patients with a history of severe congestive heart failure, clinically unstable cardiac disease or pulmonary disease were excluded from the pivotal registration studies (AZA PH GL 2003 CL 001 and AZA-AML-001) and therefore the safety and efficacy of azacitidine in these patients has not been established. 
Bolniki z anamnezo hude kongestivne srčne odpovedi, klinično nestabilne bolezni srca ali bolezni pljuč so bili iz osrednjih registracijskih študij (AZA PH GL 2003 CL 001 in AZA-AML-001) izločeni, zato varnost in učinkovitost azacitidina pri teh bolnikih nista bili ugotovljeni.
Early embryotoxicity studies in mice revealed a 44 % frequency of intrauterine embryonal death (increased resorption) after a single intraperitoneal injection of azacitidine during organogenesis. 
Študije zgodnje embriotoksičnosti pri miših so pokazale 44 % pogostnost smrti zarodka v maternici (povečana resorpcija) po enkratnem intraperitonealnem injiciranju azacitidina med organogenezo.
There is a greater risk of these events occurring during the first 2 cycles, after which they occur with less frequency in patients with restoration of haematological function. 
Tveganje, da se ti dogodki pojavijo v prvih 2 ciklih, je večje, nato se pri bolnikih pojavijo manj pogosto, krvotvorna funkcija pa se ponovno vzpostavi.
When IPSS cytogenetic subgroups were analysed, similar findings in terms of median overall survival were observed in all groups (good, intermediate, poor cytogenetics, including monosomy 7). 
Pri analiziranju citogenetskih podskupin IPSS so bili izsledki v smislu mediane celokupnega preživetja v vseh skupinah podobni (dobra, srednja, slaba citogenetika, vključno z monosomijo 7).
RAEB-T patients (21-30 % blasts) are now considered to be AML patients under the current WHO classification system. 
Bolniki z RAEB-T (21-30 % blastov) se sedaj obravnavajo kot bolniki z AML po sedanjem razvrstitvenem sistemu SZO.
• Skin infection (cellulitis). 
• kožna okužba (celulitis)
A survival benefit was also demonstrated in patients that had not achieved a complete response for Vidaza compared to CCR. 
Korist za preživetje so dokazali tudi pri bolnikih, ki niso dosegli popolnega odziva na zdravilo Vidaza v primerjavi s CCR.
This is because Vidaza may affect the way some other medicines work. 
Zdravilo Vidaza lahko vpliva na način delovanja nekaterih drugih zdravil.
Vidaza treatment was also associated with a reduction in cytopenias, and their related symptoms. 
Zdravljenje z zdravilom Vidaza je bilo povezano tudi z zmanjšanjem citopenij in z njimi povezanih simptomov.
• Blood in your urine. 
• kri v urinu
If bone marrow cellularity is ≤ 50 %, treatment should be delayed and the dose reduced according to the following table: 
Če je celularnost kostnega mozga ≤ 50 %, je treba zdravljenje preložiti in odmerek zmanjšati v skladu z naslednjo tabelo:
Azacitidine plus best supportive care (BSC) (n = 179) was compared to conventional care regimens (CCR). 
Azacitidin z najboljšo podporno oskrbo (BSC - best supportive care (n = 179) je bil primerjan z običajnimi režimi oskrbe (CCR - conventional care regimens).
Patients should be monitored for signs and symptoms of bleeding, particularly those with pre-existing or treatmentrelated thrombocytopenia. 
Pri bolnikih je treba spremljati znake in simptome krvavitev, še zlasti pri tistih, ki imajo obstoječo ali z zdravljenjem povezano trombocitopenijo.
For doses requiring more than 1 vial, the dose should be equally divided e.g., dose 150 mg = 6 mL, 2 syringes with 3 mL in each syringe. 
Za odmerke, pri katerih je potrebna več kot 1 viala, morate odmerek enakomerno razdeliti, npr. odmerek 150 mg = 6 ml, 2 brizgi s po 3 ml v vsaki brizgi.
Patients should be monitored for haematologic response/toxicity and renal toxicities (see section 4.4); a delay in starting the next cycle or a dose reduction as described below may be necessary. 
Pri bolnikih je treba spremljati hematološki odziv/toksičnost in toksičnost za ledvice (glejte poglavje 4.4); morda bo treba začetek naslednjega cikla prestaviti ali odmerek zmanjšati, kot je opisano spodaj.
• The other ingredient is mannitol (E421). 
• Druga sestavina zdravila (pomožna snov) je manitol (E421).
Dose adjustment due to haematological toxicity 
Prilagoditev odmerka zaradi hematološke toksičnosti
• Having trouble sleeping (insomnia). 
• težave s spanjem (nespečnost)
If the bone marrow cellularity is > 50 %, no dose adjustments should be made. 
Če je celularnost kostnega mozga > 50 %, ni treba prilagajati odmerka.
Cumulatively, the safety database includes 51 cases with 56 events of pericarditis, myocarditis, and/or endocarditis reported with the use of Vidaza. 
Zbirka podatkov o varnosti skupno vključuje 51 primerov s 56 pojavi perikarditisa, miokarditisa in/ali endokarditisa, o katerih so poročali pri uporabi zdravila Vidaza.
For clinical management of infectious adverse reactions, see section 4.8 Infections. 
Za klinično obravnavo neželenih učinkov, povezanih z okužbami, glejte poglavje 4.8 Okužbe.
• Pain in your belly (abdominal pain). 
• bolečine v trebuhu (abdominalne bolečine)
However, if recovery has not been achieved within 14 days, the dose should be reduced according to the following table. 
Če v 14 dneh ne pride do obnovitve, je treba odmerek zmanjšati v skladu z naslednjo tabelo.
Vidaza should be reconstituted with water for injections. 
Zdravilo Vidaza je treba rekonstituirati z vodo za injekcije.
• The active substance is azacitidine. 
• Učinkovina je azacitidin.
The Vidaza suspension may be prepared immediately before use and the reconstituted suspension should be administered within 45 minutes. 
Suspenzijo zdravila Vidaza lahko pripravite tik pred uporabo, rekonstituirano suspenzijo morate uporabiti v 45 minutah.
Once the suspension has been prepared it should be administered within 45 minutes. 
Ko je suspenzija pripravljena, jo morate uporabiti v 45 minutah.
Recommendations for safe handling 
Priporočila za varno ravnanje z zdravilom
muscle spasms, myalgia 
mišični spazmi, mialgija
On the basis of the scientific conclusions for azacitidine the CHMP is of the opinion that the benefit-risk balance of the medicinal product(s) containing azacitidine is unchanged subject to the proposed changes to the product information 
Na podlagi znanstvenih zaključkov za azacitidin odbor CHMP meni, da je razmerje med koristjo in tveganjem zdravil(-a), ki vsebuje(-jo) azacitidin, nespremenjeno ob upoštevanju predlaganih sprememb v informacijah o zdravilu.
• if you have ever had a heart condition or heart attack or any history of lung disease. 
• če ste kdaj imeli bolezen srca ali srčni infarkt ali bolezen pljuč.
Vidaza treatment should be initiated and monitored under the supervision of a physician experienced in the use of chemotherapeutic agents. 
Zdravljenje z zdravilom Vidaza mora uvesti in spremljati zdravnik, ki ima izkušnje z uporabo kemoterapevtskih zdravil.
In a few pre-specified subgroups, the OS HR reached statistical significance including patients with poor cytogenetic risk, patients with AML with myelodysplasia-related changes, patients < 75 years, female patients and white patients. 
Pri nekaj vnaprej določenih podskupinah je OS HR doseglo statistično signifikantnost, vključno z bolniki z velikim citogenetskim tveganjem, bolniki z AML s spremembami, povezanimi z mielodisplazijo, bolniki, mlajšimi od 75 let, bolnicami ženskega spola in bolniki bele rase.
Total dose (mg) = Dose (mg/m2) x BSA (m2) 
Celotni odmerek (mg) = odmerek (mg/m2) x BSA (m2)
• A fall in blood pressure when standing (orthostatic hypotension) leading to dizziness when moving to a standing or sitting position. 
• padec krvnega tlaka v stoječem položaju (ortostatska hipotenzija), ki pri premiku v stoječi ali sedeči položaj povzroči omedlevico
Annex IV Scientific conclusions and grounds for the variation to the terms of the marketing authorisation(s) 
PRILOGA IV ZNANSTVENI ZAKLJUČKI IN PODLAGA ZA SPREMEMBO POGOJEV DOVOLJENJA (DOVOLJENJ) ZA PROMET Z ZDRAVILOM
If reconstituted azacitidine comes into contact with the skin, immediately and thoroughly wash with soap and water. 
Če pride rekonstituirani azacitidin v stik s kožo, jo takoj in temeljito sperite z milom in vodo.
If large particles are present in the suspension it should be discarded. 
Če so v suspenziji prisotni večji delci, jo zavrzite.
Pharmacotherapeutic group: Antineoplastic agents, pyrimidine analogues; ATC code: L01BC07 
Farmakoterapevtska skupina: Zdravila z delovanjem na novotvorbe (citostatiki), analogi pirimidinskih baz; oznaka ATC: L01BC07
Vidaza is an anti-cancer agent which belongs to a group of medicines called ‘anti-metabolites'. 
Zdravilo Vidaza je sredstvo proti raku, ki pripada skupini zdravil, ki se imenujejo 'antimetaboliti'.
As part of the inclusion criteria, patients were required to have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. 
Kot del vključitvenih kriterijev so morali imeti bolniki stanje zmogljivosti po ECOG (Eastern Cooperative Oncology Group) 0 do 2.
Pericarditis is the most reported PT (n=35 cases) followed by endocarditis (n=10) and myocarditis (n=9). 
Najpogosteje so poročali o perikarditisu (n = 35 primerov), ki mu sledita endokarditis (n = 10) in miokarditis (n = 9).
Treatment with azacitidine is associated with anaemia, neutropenia and thrombocytopenia, particularly during the first 2 cycles (see section 4.8). 
Zdravljenje z azacitidinom je povezano z anemijo, nevtropenijo in trombocitopenijo, še zlasti v prvih 2 ciklih (glejte poglavje 4.8).
The patients at risk of tumour lysis syndrome are those with high tumour burden prior to treatment. 
Bolniki s tveganjem sindroma tumorske lize so bolniki, ki imajo pred zdravljenjem veliko tumorsko breme.
Patients with severe hepatic organ impairment should be carefully monitored for adverse events. 
Pri bolnikih s hudo okvaro jeter je treba skrbno spremljati pojav neželenih dogodkov.
Due to retention in the vial and needle, it may not be feasible to withdraw all of the suspension from the vial. 
Zaradi zadrževanja v viali in igli morda iz viale ne boste mogli izvleči vse suspenzije.
Azacitidine is cleared rapidly from plasma with a mean elimination half-life (t½) after subcutaneous administration of 41 ± 8 minutes. 
Azacitidin se hitro očisti iz plazme s povprečnim razpolovnim časom izločanja (t½) po subkutanem dajanju 41 ± 8 minut.
The relative importance of DNA hypomethylation versus cytotoxicity or other activities of azacitidine to clinical outcomes has not been established. 
Relativne pomembnosti hipometilacije DNA v primerjavi s citotoksičnostjo ali drugimi aktivnostmi azacitidina na klinični izid niso ugotavljali.
• acute myeloid leukaemia (AML). 
• akutne mieloične levkemije (AML).
Driving and using machines Do not drive or use any tools or machines if you experience side effects, such as tiredness. 
Vpliv na sposobnost upravljanja vozil in strojev Ne vozite avtomobila in ne upravljajte z orodji ali stroji, če imate neželene učinke, na primer, če ste utrujeni.
KEY: AZA = azacitidine; CCR = conventional care regimens; CI = confidence interval; 
LEGENDA: AZA = azacitidin; CCR = običajni režimi zdravljenja; IZ = interval zaupanja; RO = razmerje ogroženosti
DNA hypomethylation of aberrantly methylated genes involved in normal cell cycle regulation, differentiation and death pathways may result in gene re-expression and restoration of cancersuppressing functions to cancer cells. 
Hipometilacija DNA aberantnih metiliranih genov, ki sodelujejo pri regulaciji normalnega celičnega cikla, diferenciaciji in poti smrti, lahko povzroči ponovno izražanje genov in obnovo funkcij supresije raka za rakaste celice.
There is limited safety information available with azacitidine in patients ≥85 years (with 14 [5.9%] patients ≥85 years in AZA-AML-001 study). 
Na voljo je malo podatkov o varnosti azacitidina pri bolnikih, starih ≥85 let (pri 14 [5,9 %] bolnikih, starih ≥85 let, v študiji AZA-AML-001).
The one-year survival rates were 46.5% in patients receiving Vidaza versus 34.3% in patients receiving CCR. 
Pogostnosti enoletnega preživetja sta bili 46,5 % pri bolnikih, ki so prejemali zdravilo Vidaza, proti 34,3 % pri bolnikih, ki so prejemali CCR.
After reconstitution, the suspension should not be filtered. 
Po rekonstituciji suspenzije ne smete filtrirati.
Do not filter the suspension after reconstitution since this could remove the active substance. 
Ne filtrirajte rekonstituirane suspenzije, ker bi s tem lahko odstranili zdravilno učinkovino.
% Dose in the next cycle, if recovery* is not achieved within 14 days 
% odmerka v naslednjem ciklu, če ni obnovitve* v 14 dneh
Dose mg/m2 
Odmerek mg/m2
In patients with one or more cytogenetic abnormalities at baseline, the percentage of patients with a major cytogenetic response was similar in the azacitidine and combined CCR groups. 
Pri bolnikih z eno ali več citogenetskih abnormalnosti ob izhodišču je bil odstotek bolnikov z bistvenim citogenetskim odzivom podoben v skupini z azacitidinom in v kombinirani skupini CCR.
Clinically significant inhibitory or inductive effects of azacitidine on cytochrome P450 enzymes are unlikely (see section 5.2). 
Klinično značilni zaviralni ali spodbujevalni učinki azacitidina na encime citokroma P450 niso verjetni (glejte poglavje 5.2).
One vial contains 100 mg azacitidine. 
Ena viala vsebuje 100 mg azacitidina.
New injections should be given at least 2.5 cm from the previous site and never into areas where the site is tender, bruised, red, or hardened. 
Nove injekcije je treba dati vsaj 2,5 cm od prejšnjega mesta injiciranja in nikoli na predel, ki je občutljiv, poškodovan, pordel ali otrdel.
The individual baseline parameters were comparable between the Vidaza and CCR groups. 
Posamezni izhodiščni parametri so bili med skupino z zdravilom Vidaza in skupino s CCR primerljivi.
These complications are caused by the product of dying cancer cells and may include the following: changes to blood chemistry; high potassium, phosphorus, uric acid, and low calcium consequently leading to changes in kidney function, heartbeat, seizures, and sometimes death. 
Te zaplete povzročijo razgradni produkti odmirajočih rakavih celic in lahko vključujejo: spremembe kemijske sestave krvi; visoke vsebnosti kalija, fosforja, sečne kisline in nizke vsebnosti kalcija, ki posledično vodijo do sprememb delovanja ledvic, utripa srca, epileptičnih napadov in včasih smrt.
It is thought to work by altering the way the cell turns genes on and off and also by interfering with the production of new RNA and DNA. 
Domneva se, da deluje tako, da spremeni način, na katerega celica vključuje in izključuje gene, in tudi tako, da ovira nastajanje nove RNK in DNK.
Your doctor, pharmacist or nurse are responsible for storing Vidaza. 
Za shranjevanje zdravila Vidaza je odgovoren vaš zdravnik, farmacevt ali medicinska sestra.
No specific modification to the starting dose is recommended for patients with hepatic impairment prior to starting treatment; subsequent dose modifications should be based on haematology laboratory values. 
Pri bolnikih z okvaro jeter pred začetkom zdravljenja se ne priporoča posebna prilagoditev začetnega odmerka; kasnejše prilagoditve odmerka naj temeljijo na hematoloških laboratorijskih vrednostih.
Therefore, CYP enzyme induction or inhibition by azacitidine at clinically achievable plasma concentrations is unlikely. 
Zato ni verjetno, da bi azacitidin induciral ali zaviral encim CYP pri klinično dosegljivih koncentracijah v plazmi.
In addition, although the study was not powered to demonstrate a statistically significant difference when comparing azacitidine to the preselection CCR treatment groups, the survival of Vidaza treated patients was longer when compared to CCR treatment options BSC alone, low-dose cytarabine plus BSC and were similar when compared to standard intensive chemotherapy plus BSC. 
Poleg tega, čeprav študija ni bila zasnovana tako, da bi dokazala statistično signifikantno razliko pri primerjavi azacitidina z vnaprej izbranimi skupinami, zdravljenimi s CCR, je bilo preživetje bolnikov, zdravljenih z zdravilom Vidaza, daljše, ko so jih primerjali z opcijama zdravljenja CCR, samo BSC ali citarabin v majhnem odmerku skupaj z BSC, podobne pa so bile, če so jih primerjali s standardno intenzivno kemoterapijo skupaj z BSC.
None of these adverse reactions led to discontinuation of azacitidine, or reduction of azacitidine dose in the pivotal studies. 
Noben od teh neželenih učinkov ni bil vzrok za prekinitev zdravljenja z azacitidinom ali zmanjšanja odmerka azacitidina v osrednjih študijah.
Before giving you Vidaza, your doctor will give you another medicine to prevent nausea and vomiting at the start of each treatment cycle. 
Preden vam bo zdravnik predpisal zdravilo Vidaza, vam bo predpisal druga zdravila za preprečevanje slabosti in bruhanja na začetku vsakega cikla,.
Azacitidine becomes incorporated into the genetic material of cells (ribonucleic acid (RNA) and deoxyribonucleic acid (DNA)). 
Azacitidin se vključi v genetski material celic (ribonukleinsko kislino (RNK) in deoksiribonukleinsko kislino (DNK)).
• Injection site reaction including redness, pain or a skin reaction. 
• reakcija na mestu injiciranja, vključno s pordelostjo, bolečino ali kožno reakcijo
Azacitidine can be administered to patients with renal impairment without initial dose adjustment (see section 5.2). 
Azacitidin lahko dajemo bolnikom z okvaro ledvic brez začetne prilagoditve odmerka (glejte poglavje 5.2).
What Vidaza is and what it is used for What you need to know before you use Vidaza How to use Vidaza 
Kaj je zdravilo Vidaza in za kaj ga uporabljamo Kaj morate vedeti, preden boste uporabili zdravilo Vidaza Kako uporabljati zdravilo Vidaza Možni neželeni učinki
CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT 100 mg 
VSEBINA, IZRAŽENA Z MASO, PROSTORNINO ALI ŠTEVILOM ENOT 100 mg
Due to the potential serious adverse reactions in the nursing child, breast-feeding is contraindicated during azacitidine therapy. 
Zaradi možnih resnih neželenih učinkov pri dojenih otrocih je dojenje med zdravljenjem z azacitidinom kontraindicirano.
Uncommon Rare 
Neznana pogostnost
In case of an anaphylactic-like reaction, treatment with azacitidine should be immediately discontinued and appropriate symptomatic treatment initiated. 
V primeru reakcije, podobne anafilaktični, je treba zdravljenje z azacitidinom takoj prekiniti in uvesti ustrezno simptomatsko zdravljenje.
• Bleeding inside your head. 
• krvavitev v glavi
In studies to assess inhibition of a series of P450 isoenzymes (CYP 1A2, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1 and 3A4) azacitidine up to 100 μM did not produce inhibition. 
V študijah za ocenitev zaviranja vrste izoencimov P450 (CYP 1A2, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1 in 3A4) azacitidin do 100 µM ni povzročil zaviranja.
The Cox PH model adjusted for pre-specified baseline prognostic factors defined a HR for Vidaza versus CCR of 0.80 (95% CI= 0.66, 0.99; p = 0.0355). 
Coxov PH model, prilagojen za vnaprej določene izhodiščne prognostične dejavnike, je definiral HR za zdravilo Vidaza proti CCR 0,80 (95 % IZ= 0,66; 0,99; p = 0,0355).
Vidaza plus BSC (n=241) was compared to CCR. 
Zdravilo Vidaza skupaj z BSC (n=241) so primerjali s CCR.
• Allergic (hypersensitivity) reaction. 
• alergijska (preobčutljivostna) reakcija
Before starting treatment, male patients should be advised to seek counselling on sperm storage. 
Priporoča se, da se moški bolniki pred začetkom zdravljenja posvetujejo o shranitvi sperme.
What Vidaza is and what it is used for 
Kaj je zdravilo Vidaza in za kaj ga uporabljamo
The most common serious adverse reactions noted from the pivotal study (AZA PH GL 2003 CL 001) included febrile neutropenia (8.0 %) and anaemia (2.3 %), which were also reported in the supporting studies (CALGB 9221 and CALGB 8921). 
Najbolj pogosta resna neželena učinka, opažena v osrednji študiji (AZA PH GL 2003 CL 001), sta bila febrilna nevtropenija (8,0 %) in anemija (2,3 %), o katerih so poročali tudi v podpornih študijah (CALGB 9221 in CALGB 8921).
Storage of the reconstituted product 
Shranjevanje rekonstituiranega zdravila
Most haematological adverse reactions were managed by routine monitoring of complete blood counts and delaying azacitidine administration in the next cycle, prophylactic antibiotics and/or growth factor support (e.g. G-CSF) for neutropenia and transfusions for anaemia or thrombocytopenia as required. 
Večino hematoloških neželenih učinkov so obvladovali z rutinskim spremljanjem kompletne krvne slike in preložitvijo zdravljenja z azacitidinom v naslednji cikel, s profilaktičnim dajanjem antibiotikov in/ali podporo rastnih dejavnikov (npr. G-CSF) za nevtropenijo in s transfuzijami za anemijo ali trombocitopenijo, kot je bilo potrebno.